Clinical trial · no report yet · Phase 3
IMmotion010
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
- NCT03024996 ↗
- Terminated
- Hoffmann-La Roche
- 98 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 48 | |
| YouTube | 27 | |
| Podcasts | 23 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients With Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy
- Phase
- Phase 3
- Status
- Terminated
- Conditions
- Renal Cell Carcinoma
- Interventions
- Atezolizumab; Placebo
- Arms
- Atezolizumab · Experimental
- Placebo · Placebo comparator
- Enrollment
- 778
- Primary outcomes
- Investigator-assessed Disease-Free Survival (DFS)
- Sponsor
- Hoffmann-La Roche
- Start
- Jan 3, 2017
- Primary completion
- May 3, 2022
- Results posted
- Yes
- Registry record
- NCT03024996 · updated Aug 3, 2023
Publications
linked from the registry- Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, Procopio G, Massari F, Zibelman M, Antonyan I, Huseni M, Basu D, Ci B, Leung W, Khan O, Dubey S, Bex A. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022 Oct 1;400(10358):1103-1116. doi: 10.1016/S0140-6736(22)01658-0. Epub 2022 Sep 10. PubMed 36099926
- Marconi L, Sun M, Beisland C, Klatte T, Ljungberg B, Stewart GD, Dabestani S, Choueiri TK, Bex A. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials. Clin Genitourin Cancer. 2021 Apr;19(2):e92-e99. doi: 10.1016/j.clgc.2020.12.005. Epub 2021 Jan 7. PubMed 33526329